Redwood City, CA (PRWEB) May 21, 2014
Neural ID, the provider of the only collaborative biosignal analytics platform spanning the pharmaceutical lifecycle, today announced a significant release of their flagship product IWS. This release adds value to IWS’s unique combination of expert-driven machine learning, massive data reduction and interoperable data formats. The core improvements are designed to improve analysis of preclinical cardiac safety data and support regulated customers’ Good Laboratory Practice (GLP) traceability needs. These enhancements are being deployed along with additional US East Coast customer support services.
New features in IWS version 2.4 include:
“We are committed to continually extending IWS capabilities to deliver the most comprehensive solution to our customers while ensuring that IWS can be easily implemented in the broadest number of research scenarios,” said Timothy Carruthers, CEO, Neural ID. “IWS version 2.4 is an excellent example of that ethos – the product will help our customers maintain GLP practices through enhanced traceability without requiring the additional cost of another process. IWS version 2.4’s enhancements have already resulted in a Top-10 pharmaceutical company deploying the new release.”
About Neural ID
Neural ID provides the only collaborative biosignal analytics platform spanning the pharmaceutical lifecycle. From Discovery through Clinical and Health Information, Neural ID delivers a scalable enterprise solution addressing the industry’s productivity crisis. Our flagship product, Intelligent Waveform Solution (IWS) delivers expert-driven machine learning, massive data reduction and an interoperable data format to help customers make better decisions faster, leading to increased product revenues and reduced development costs. Neural ID, based in Redwood City, CA, launched IWS in 2013. Further information is available at http://www.neuralid.com
Email: jmccargo (at) evcgroup (dot) com